双鹭药业：关于参股公司长风药业股份有限公司拟在香港联交所主板挂牌上市的公告

Core Insights - Double-Crane Pharmaceutical announced that its associate company, Changfeng Pharmaceutical Co., Ltd., is expected to officially list on the Hong Kong Stock Exchange on October 8, 2025, with stock code 02652.HK [1] - Changfeng Pharmaceutical plans to globally offer 41.198 million shares at a price of HKD 14.75 per share [1] - After the offering, Double-Crane Pharmaceutical will hold a total of 15.165653 million shares in Changfeng Pharmaceutical, representing 3.68% of the total shares post-issuance, with a lock-up period of 12 months following the listing [1]